The U.S. Food and Drug Administration is tightening restrictions on a gene therapy used to treat Duchenne muscular dystrophy ...

Risk of “acute, serious, and life-threatening” heart inflammation is now on the label of Sarepta's gene therapy for Duchenne ...

A rare disease that has cut off children from the outside world now potentially has a cure. A clinical trial to treat severe ...

Fred Hutch bioengineer Dr. Matthias Stephan is working to develop a special foam that could help make gene therapy for blood ...

Coave Therapeutics has announced its lead gene therapy program, CoTx-10, for the treatment of retinal vascular diseases, such ...

Krystal Biotech drives Vyjuvek growth, premium margins, global expansion, a $1B goal, and pipeline data ahead with a $219.50 ...

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the grand opening of its East Coast ...

Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed ...

A Greer couple is hosting a fundraiser to support a costly gene editing procedure for their two children, who suffer from a ...

The updated label now includes a boxed warning and a new “limitation of use" in addition to the removal of the prior ...

The article 🌱 Patch AM: New gene therapy center opens at Cincinnati Children's Hospital appeared first on Cincinnati Patch.

Corneal edema involves fluid accumulation in the cornea, leading to cloudiness and vision impairment. The market is growing due to an aging population and increasing cataract and glaucoma surgeries.